Thank you, Fred. Our Q3 '19 revenue declined to $463,000 versus $740,000 in Q3 '18. Hardware sales decreased by $186,000, due to smaller new customer deployments and lower volume of lock orders.Hardware sales declined by 186,000 with smaller new customer deployments, and a lower volume of lock orders.Software license revenue decreased by $112,000 from Q3 '18, due to smaller orders and more diverse customers. Software license revenue has been negatively impacted by the company's transition to the subscription model from historical license sale model. This net effect of the transition is to decrease the upfront revenue realized from new software engagement and replace it with a recurring revenue stream with the potential to be significantly larger over time.Service revenue increased by $12,000 to $237,000 in Q3 '19 from the prior period. Service revenue is made up 52% of revenues in Q3 '19, up from 31% in Q3 '18 with approximately 95% of service revenue classifies as recurring revenue.Gross Margin in Q3 '19 was negative 12% compared to negative 27% in Q3 '18, due primarily to the impact of the non-cash offer license amortization expense. Excluding the non-cash amortization expense, gross margin would have been 50% in Q3 '19, verses 62% in Q3 '18, with a decline due to lower levels of software license fees and product mix.Q3 '19 operating expenses decreased 226,000 to $1.2 million from $1.4 million in Q3, due to primarily lower SG&A expenses related to reduction in marketing and administrative payroll and non-cash compensations, partially offset by increased sales, payroll and legal fees.BIO-key's Q3 '19 net loss improved to $1.9 million, or loss of $0.13 per basic and diluted share as compared to $3.1 million or loss of $0.23 per basic share after preferred dividends in Q3 '18. The prior year period included deems dividend relating to the repricing of outstanding warrants of $1.4 million or a $0.11 per share.Per share results are based on 14. 4 and 13.1 million weighted average basic and diluted shares outstanding in Q3 '19 and Q3 '18 respectively.On September, 30 2019, BIO-key had networking capital worth of approximately 0.5 million versus approximately 3 million at December, 31 2019, which does not reflect the benefit of the financing that was mentioned in our press release earlier today.The equity financing is a private placement with limited number of investors and is expected to price at a premium to the current market price of the company's stock. This funding is intended to support our near term working capital needs, as well as the required repayments pursuant to the interim convertible debt financing obtained earlier this year. We are limited in what more we can say about this funding, except that we are in the process of closing and therefore expect to announce that in short order.With that overview, we can move to questions. Operator, could you please start the question-and-answer session.